Oral contraceptive use as a risk factor for premenopausal breast cancer: A meta-analysis

Mayo Clinic Proceedings

Volumn 81, Issue 10, 2006, Pages 1290-1302

  Kahlenborn, Chris ^a,e   Modugno, Francesmary ^b   Potter, Douglas M ^c   Severs, Walter B ^d  

^a University of Pittsburgh Medical Center   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER RISK; CASE REPORT; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; META ANALYSIS; NULLIPARA; ORAL CONTRACEPTION; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; REVIEW;

EID: 33749247786     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.10.1290     Document Type: Article

References (134)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published correction appears in CA Cancer J Clin. 2005;55:259], CA Cancer J Clin. 2005;55:10-30.
2. Breast cancer facts and figures 2003-2004. Atlanta (GA): American Cancer Society; c2003. Available at: http://www.cancer.org/downloads/STT /CAFF2003BrFPWSecured.pdf. Accessed September 5, 2006.
3. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1973-1999. Bethesda (MD): National Cancer Institute; 2002. Available at: http://seer.cancer.gov/csr/1973_1999/. Accessed September 5, 2006.
4. Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med. 1994;330:81-87.
5. McTiernan A, Thomas DB. Evidence for a protective effect of lactation on risk of breast cancer in young women: results from a case-control study. Am J Epidemiol. 1986;124:353-358.
6. Lowe CR, MacMahon B. Breast cancer and reproductive history of women in South Wales. Lancet. 1970;1:153-156.
7. Mirra AP, Cole P, MacMahon B. Breast cancer in an area of high parity: Sao Paulo, Brazil. Cancer Res. 1971;31:77-83.
8. Chlebowski RT, Hendrix SL, Langer RD, et al, WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253.
9. World Health Organization International Agency for Research on Cancer. IARC monographs programme finds combined estrogen-progestogen contraceptives and menopausal therapy are carcinogenic to humans [press release 167], July 29, 2005. Available at: www.iarc.fr/ENG/Press_Releases/pr167a .html. Accessed September 1, 2006.
10. Romieu I, Berlin JA, Colditz G. Oral contraceptives and breast cancer: review and meta-analysis. Cancer. 1990;66:2253-2263.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996;54(suppl): 1S-106S.
12. Thomas DB. Oral contraceptives and breast cancer, review of the epidemiologic literature. Contraception. 1991;43:597-642.
13. Hawley W, Nuovo J, DeNeef CP, Carter P. Do oral contraceptive agents affect the risk of breast cancer? A meta-analysis of the case-control reports. J Am Board Fam Pract. 1993;6:123-135.
14. Delgado-Rodriguez M, Sillero-Arenas M, Rodriguez-Contreras R, Lopez Gigosos R, Galvez Vargas R. Oral contraceptives and breast cancer: a meta-analysis. Rev Epidemiol Sante Publique. 1991;39;165-181.
15. Rushton L, Jones DR. Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br J Obstet Gynaecol. 1992;99:239-246.
16. Russo J, Hu YF, Silva ID, Russo IH. Cancer risk related to mammary gland structure and development. Microsc Res Tech. 2001;52:204-223.
17. Kelsey JL. A review of the epidemiology of human breast cancer. Epidemiol Rev. 1979;1:74-109.
18. Helmrich SP, Shapiro S, Rosenberg L, et al. Risk factors for breast cancer. Am J Epidemiol. 1983;117:35-45.
19. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980;243:1635-1639.
20. Stanford JL, Brinton LA, Hoover RN. Oral contraceptives and breast cancer: results from an expanded case-control study. Br J Cancer. 1989;60:375-381.
21. Ursin G, Aragaki CC, Paganini-Hill A, Siemiatycki J, Thompson WD, Haile RW. Oral contraceptives and premenopausal bilateral breast cancer: a case-control study. Epidemiology. 1992;3:414-419.
22. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet. 1983;2:926-930.
23. Morabia A, Szklo M, Stewart W, Schuman L, Thomas DB. Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighborhood controls. Prev Med. 1993;22:178-186.
24. Vessey M, Baron J, Doll R, McPherson K, Yeates D. Oral contraceptives and breast cancer: final report of an epidemiological study. Br J Cancer. 1983;47:455-462.
25. Schildkraut JM, Hulka BS, Wilkinson WE. Oral contraceptives and, breast cancer: a case-control study with hospital and community controls. Obstet Gynecol. 1990;76:395-402.
26. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control. 1992;3:475-479.
27. Rossing MA, Stanford JL, Weiss NS, Habel LA. Oral contraceptive use and risk of breast cancer in middle-aged women. Am J Epidemiol. 1996;144:161-164.
28. Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C. Oral contraceptives and breast cancer in northern Italy: final report from a case-control study. Br J Cancer. 1993;68:568-571.
29. La Vecchia C, Negri E, Franceschi S, et al. Oral contraceptives and breast cancer: a cooperative Italian study. Int J Cancer. 1995;60:163-167.
30. Tavani A, Gallus S, La Vecchia C, et al. Risk factors for breast cancer in women under 40 years. Eur J Cancer. 1999;35:1361-1367.
31. Sanderson M, Shu XO, Jin F, et al. Abortion history and breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer. 2001;92:899-905.
32. Hislop TG, Goldman AJ, Elwood JM, Brauer G, Kan L. Childhood and recent eating patterns and risk of breast cancer. Cancer Detect Prev. 1986;9:47-58.
33. Rohan TE, McMichael AJ. Oral contraceptive agents and breast cancer: a population-based case-control study. Med J Aust. 1988;149:520-526.
34. Segala C, Gerber M, Richardson S. The pattern of risk factors for breast cancer in a southern France population: interest for a stratified analysis by age at diagnosis. Br J Cancer. 1991;64:919-925.
35. Siskind V, Schofield F, Rice D, Bain C. Breast cancer and breastfeeding: results from an Australian case-control study. Am J Epidemiol. 1989;130:229-236.
36. Bustan MN, Coker AL, Addy CL, Macera CA, Greene F, Sampoerno D. Oral contraceptive use and breast cancer in Indonesia. Contraception. 1993;47: 241-249.
37. Ngelangel C, Lacaya LB, Cordero C, Laudico AV. Risk factors for breast cancer among Filipino women. Philipp J Intern Med. 1994;32:231-236.
38. Ravnihar B, Primic Zakelj M, Kosmelj K, Stare J. A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. Neoplasma. 1988;35:109-121.
39. Talamini R, La Vecchia C, Franceschi S, et al. Reproductive and hormonal factors and breast cancer in a Northern Italian population. Int J Epidemiol. 1985;14:70-74.
40. Wang QS, Ross RK, Yu MC, Ning JP, Henderson BE, Kimm HT. A case-control study of breast cancer in Tianjin, China. Cancer Epidemiol Biomarkers Prev. 1992;1:435-439.
41. Ellery C, MacLennan R, Berry G, Shearman RP. A case-control study of breast cancer in relation to the use of steroid contraceptive agents. Med J Aust. 1986;144:173-176.
42. Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L. Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat. 1998;50:175-184.
43. Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87:827-835.
44. Chie WC, Li CY, Huang CS, Chang KJ, Yen ML, Lin RS. Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives. Int J Cancer. 1998;77:219-223.
45. UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet. 1989;1:973-982.
46. Clavel F, Andrieu N, Gairard B, et al. Oral contraceptives and breast cancer: a French case-control study. Int J Epidemiol. 1991;20:32-38.
47. Ewertz M. Oral contraceptives and breast cancer risk in Denmark. Eur J Cancer. 1992;28A:1176-1181.
48. Gomes AL, Guimaraes MD, Gomes CC, Chaves IG, Gobbi H, Camargos AF. A case-control study of risk factors for breast cancer in Brazil, 1978-1987. Int J Epidemiol. 1995;24:292-299.
49. Le MG, Bachelot A, Doyen F, Kramar A. A study on the association between the use of oral contraception and cancer of the breast or cervix: preliminary findings of a French study [in French]. Contracept Fertil Sex (Paris). 1985;13:553-558.
50. Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst. 1987;79:1247-1254.
51. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Risk factors for breast cancer by age and menopausal status: a case-control study in Singapore. Cancer Causes Control. 1992;3:313-322.
52. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025-2032.
53. Marcus PM, Baird DD, Millikan RC, Moorman PG, Qaqish B, Newman B. Adolescent reproductive events and subsequent breast cancer risk. Am J Public Health. 1999;89:1244-1247.
54. Marubini E, Decarli A, Costa A, et al. The relationship of dietary intake and serum levels of retinol and beta-carotene with breast cancer: results of a case-control study. Cancer. 1988;61:173-180.
55. McCredie MR, Dite GS, Giles GG, Hopper JL. Breast cancer in Australian women under the age of 40. Cancer Causes Control. 1998;9:189-198.
56. McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer. 1987;56:653-660.
57. Meirik O, Lund E, Adami HO, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and breast cancer in young women: a joint national case-control study in Sweden and Norway. Lancet. 1986;2:650-654.
58. Moorman PG, Millikan RC, Newman B. Oral contraceptives and breast cancer among African-American women and white women. J Natl Med Assoc. 2001;93:329-334.
59. Newcomb PA, Longnecker MP, Storer BE, et al. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control. 1996; 7:525-532.
60. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and combined oral contraceptives: results from a multinational study. Br J Cancer. 1990;61:110-119.
61. Olsson H, Moller TR, Ranstam J. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst. 1989;81:1000-1004.
62. Palmer JR, Rosenberg L, Rao RS, et al. Oral contraceptive use and breast cancer risk among African-American women. Cancer Causes Control. 1995;6:321-331.
63. Paul C, Skegg DC, Spears GF. Oral contraceptives and risk of breast cancer. Int J Cancer. 1990;46:366-373.
64. Primic-Zakelj M, Evstifeeva T, Ravnihar B, Boyle P. Breast-cancer risk and oral contraceptive use in Slovenian women aged 25 to 54. Int J Cancer. 1995;62:414-420.
65. Rookus MA, van Leeuwen FE, Netherlands Oral Contraceptives and Breast Cancer Study Group. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Lancet. 1994;344:844-851.
66. Rosenberg L, Palmer JR, Clarke EA, Shapiro S. A case-control study of the risk of breast cancer in relation to oral contraceptive use. Am J Epidemiol. 1992;136:1437-1444.
67. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives [published correction appears in Am J Epidemiol. 2000;151:1134]. Am J Epidemiol. 2000;151:396-403.
68. Tessaro S, Beria JU, Tomasi E, Barros AJ. Oral contraceptive and breast cancer: a case-control study [in Portuguese]. Rev Saude Publica. 2001;35:32-38.
69. Traina A, Cusimano R, Liquori M, et al. Oral contraceptive use and breast cancer risk in areas with different incidence: a case-control study among young women. Ann N Y Acad Sci. 1996;784:564-569.
70. Ursin G, Wu AH, Hoover RN, et al. Breast cancer and oral contraceptive use in Asian-American women. Am J Epidemiol. 1999;150:561-567.
71. Weinstein AL, Mahoney MC, Nasca PC, Leske MC, Varma AO. Breast cancer risk and oral contraceptive use: results from a large case-control study. Epidemiology. 1991;2:353-358.
72. Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Cancer. 1993;71(suppl):1506-1517.
73. White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst. 1994; 86:505-514.
74. Yuan JM, Yu MC, Ross RK, Gao YT, Henderson BE. Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res. 1988;48:1949-1953.
75. Rosenberg L, Palmer JR, Rao RS, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol. 1996;143:25-37.
76. The Centers for Disease Control Cancer and Steroid Hormone Study. Long-term oral contraceptive use and the risk of breast cancer. JAMA. 1983;249:1591-1595.
77. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Oral-contraceptive use and the risk of breast cancer. N Engl J Med. 1986;315:405-411.
78. Stadel BV, Lai SH, Schlesselman JJ, Murray P. Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception. 1988;38: 287-299.
79. Mayberry RM. Age-specific patterns of association between breast cancer and risk factors in black women, ages 20 to 39 and 40 to 54. Ann Epidemiol. 1994;4:205-213.
80. Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S. Breast cancer before age 45 and oral contraceptive use: new findings. Am J Epidemiol. 1989;129:269-280.
81. Lund E, Meirik O, Adami HO, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and premenopausal breast cancer in Sweden and Norway: possible effects of different pattern of use. Int J Epidemiol. 1989;18:527-532.
82. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
83. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713-1727.
84. Althuis MD, Brogan DR, Coates RJ, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer. 2003;88:50-57.
85. Nomura AM, Kolonel LN, Hirohata T, Lee J. The association of replacement estrogens with breast cancer. Int J Cancer. 1986;37:49-53.
86. McGregor H, Land CE, Choi K, et al. Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950-69. J Natl Cancer Inst. 1977;59:799-811.
87. Kirschstein RL, Rabson AS, Rusten GW. Infiltrating duct carcinoma of the mammary gland of a rhesus monkey after administration of an oral contraceptive: a preliminary report. J Natl Cancer Inst. 1972;48:551-556.
88. Geil RG, Lamar JK. FDA studies of estrogen, progestogens, and estrogen/progestogen combinations in the dog and monkey. J Toxicol Environ Health. 1977;3:179-193.
89. Shubik P. Oral contraceptives and breast cancer: laboratory evidence. IARC Sci Publ. 1985;(65):33-35.
90. Lanari C, Molinolo AA, Pasqualini CD. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett. 1986;33:215-223.
91. Welsch CW, Adams C, Lambrecht LK, Hassett CC, Brooks CL. 17beta-oestradiol and Enovid mammary tumorigenesis in C3H/HeJ female mice: counteraction by concurrent 2-bromo-alpha-ergocryptine. Br J Cancer. 1977;35:322-328.
92. Kahn RH, Baker BL. Effect of long-term treatment with norethynodrel on A-J and CSH-HeJ mice. Endocrinology. 1969;84:661-668.
93. Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol. 1989;20:1139-1144.
94. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990;50:7415-7421.
95. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science. 1990;249:970-971.
96. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science. 1990;249:1007-1011.
97. Larimore WL, Stanford JB. Postfertilization effects of oral contraceptives and their relationship to informed consent. Arch Fam Med. 2000;9:126-133.
98. Norman RJ, McLoughlin JW, Borthwick GM, et al. Inhibin and relaxin concentrations in early singleton, multiple, and failing pregnancy: relationship to gonadotropin and steroid profiles. Fertil Steril. 1993;59:130-137.
99. Stewart DR, Overstreet JW, Nakajima ST, Lasley BL. Enhanced ovarian steroid secretion before implantation in early human pregnancy. J Clin Endocrinol Metab. 1993;76:1470-1476.
100. Another look at the pill and breast cancer. Lancet. 1985;2:985-987.
101. Hulka BS. Oral contraceptives: the good news. JAMA. 1983;249:1624-1625.
102. Olsson H, Borg A, Femo M, Moller TR, Ranstam J. Early oral contraceptive use and premenopausal breast cancer: a review of studies performed in southern Sweden. Cancer Detect Prev. 1991;15:265-271.
103. Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev. 1993;15:80-97.
104. Colton T, Greenberg ER, Noller K, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy: further follow-up. JAMA. 1993;269:2096-2100.
105. Olsson H, Ranstam J, Baldetorp B, et al. Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. Cancer. 1991;67:1285-1290.
106. Olsson H, Borg A, Ferno M, Ranstam J, Sigurdsson H. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst. 1991;83:1483-1487.
107. Ranstam J, Olsson H, Garne JP, Aspegren K, Janzon L. Survival in breast cancer and age at start of oral contraceptive usage. Anticancer Res. 1991; 11:2043-2046.
108. Gammon MD, Hibshoosh H, Terry MB, et al. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev. 1999;8:413-419.
109. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179: 577-582.
110. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, eds. Patient Compliance In Medical Practice and Clinical Trials. New York: Raven Press; 1991:195-207.
111. Balassone ML. Risk of contraceptive discontinuation among adolescents. J Adolesc Health Care. 1989;10:527-533.
112. Nischan P, Ebeling K, Thomas DB, Hirsch U. Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol. 1993;138:697-703.
113. Alexander FE, Roberts MM, Huggins A. Risk factors for breast cancer with applications to selection for the prevalence screen. J Epidemiol Community Health. 1987;41:101-106.
114. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ. 1999;318:96-100.
115. Calle EE, Martin LM, Thun MJ, Miracle HL, Heath CW Jr. Family history, age, and risk of fatal breast cancer. Am J Epidemiol. 1993;138:675-681.
116. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer. 2003;105:844-850.
117. Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000;284:1791-1798.
118. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control. 1997;8:65-72.
119. Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer. 1984;54:139-144.
120. Kay CR, Hannaford PC. Breast cancer and the pill: a further report from the Royal College of General Practitioners' oral contraception study. Br J Cancer. 1988;58:675-680.
121. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 2002;11:1375-1381.
122. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years [published correction appears in CMAJ. 1993;148:718]. CMAJ. 1992;147: 1459-1476.
123. Mills PK, Beeson WL, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer. 1989;64:591-597.
124. Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study. Cancer Causes Control. 1995;6:416-424.
125. Tomasson H, Tomasson K. Oral contraceptives and risk of breast cancer: a historical prospective case-control study. Acta Obstet Gynecol Scand. 1996;75:157-161.
126. Trapido EJ. A prospective cohort study of oral contraceptives and breast cancer. J Natl Cancer Inst. 1981;67:1011-1015.
127. Tryggvadottir L, Tulinius H, Gudmundsdottir GB. Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect of birth year. Br J Cancer. 1997;75:139-143.
128. Van Hoften C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, Leufkens HG. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer. 2000;87:591-594.
129. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer. 1989;59:613-617.
130. Dickey RP, Stone SC. Progestational potency of oral contraceptives. Obstet Gynecol. 1976;47:106-112.
131. Staffa JA, Newschaffer CJ, Jones JK, Miller V. Progestins and breast cancer: an epidemiologic review. Fertil Steril. 1992;57:473-491.
132. Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB. Depot medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and New Zealand studies. JAMA. 1995;273:799-804.
133. Anderson GL, Limacher M, Assaf AR, et al, Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
134. Tyrer L. Introduction of the pill and its impact. Contraception. 1999; 59(suppl):11S-16S.